Rare fat disorder drug under microscope: new safety data emerges
NCT ID NCT04026178
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the safety of a daily shot called metreleptin (brand name Myalept) in 11 people with generalized lipodystrophy, a rare condition where the body loses fat tissue. The main goal was to see if the body makes antibodies against the drug, which could affect how well it works or cause side effects. Results help doctors understand long-term risks and ensure the treatment remains safe for managing this lifelong disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Endocrinology Research Associates
Columbus, Ohio, 43201, United States
-
Ochsner Clinic
New Orleans, Louisiana, 70121, United States
-
Ohio State University
Columbus, Ohio, 43203, United States
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
-
Univ. Alabama-Birmingham
Birmingham, Alabama, 35294, United States
-
University Texas Southwestern INT
Dallas, Texas, 75390, United States
-
University of Michigan
Ann Arbor, Michigan, 48109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.